{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:54:15Z","timestamp":1790744055784,"version":"4.1.0"},"reference-count":154,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Pediatric and Adolescent Health Care"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.cppeds.2018.08.015","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T19:47:36Z","timestamp":1537818456000},"page":"250-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders"],"prefix":"10.1016","volume":"48","author":[{"given":"Martine","family":"Lamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cppeds.2018.08.015_bib0001","series-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6706a1","article-title":"Prevalence of autism spectrum disorder among children aged 8 years \u2013 autism and developmental disabilities monitoring network, 11 sites, United States, 2014","volume":"67","author":"Baio","year":"2018","journal-title":"MMWR Surveill Summ"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0003","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/DBP.0b013e3181d5d03b","article-title":"Autism spectrum disorder and co-occurring developmental, psychiatric, and medical conditions among children in multiple populations of the United States","volume":"31","author":"Levy","year":"2010","journal-title":"J Dev Behav Pediatr"},{"issue":"8","key":"10.1016\/j.cppeds.2018.08.015_bib0004","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/CHI.0b013e318179964f","article-title":"Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample","volume":"47","author":"Simonoff","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0006","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/cap.2009.0121","article-title":"Aripiprazole in the treatment of irritability in pediatric patients (aged 6\u201317 years) with autistic disorder: results from a 52-week, open-label study","volume":"21","author":"Marcus","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"10.1016\/j.cppeds.2018.08.015_bib0007","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4088\/JCP.09m05933","article-title":"Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study","volume":"72","author":"Marcus","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0008","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/acps.12644","article-title":"Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review","volume":"135","author":"Jobski","year":"2017","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.annepidem.2011.10.007","article-title":"High prescription drug use and associated costs among medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network","volume":"22","author":"Logan","year":"2012","journal-title":"Ann Epidemiol"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/cap.2013.0119","article-title":"Aberrant behaviors and co-occurring conditions as predictors of psychotropic polypharmacy among children with autism spectrum disorders","volume":"25","author":"Logan","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0011","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.cppeds.2018.08.015_bib0012","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Pandina","year":"2007","journal-title":"J Autism Dev Disord"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0013","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pedhc.2011.02.008","article-title":"Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis","volume":"26","author":"Sharma","year":"2012","journal-title":"J Pediatr Health Care"},{"issue":"11","key":"10.1016\/j.cppeds.2018.08.015_bib0014","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","article-title":"Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study","volume":"44","author":"Troost","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.cppeds.2018.08.015_bib0015","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months","volume":"162","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0016","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1089\/cap.2015.0005","article-title":"Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial","volume":"25","author":"Aman","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"10.1016\/j.cppeds.2018.08.015_bib0017","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10803-012-1723-5","article-title":"Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study","volume":"43","author":"Kent","year":"2013","journal-title":"J Autism Dev Disord"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0018","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bcpt.12570","article-title":"9-hydroxyrisperidone-induced hyperprolactinaemia in thai children and adolescents with autism spectrum disorder","volume":"119","author":"Ngamsamut","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0019","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/cap.2011.0109","article-title":"Risk of hyperprolactinemia and sexual side effects in males 10\u201320 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone","volume":"22","author":"Roke","year":"2012","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"10.1016\/j.cppeds.2018.08.015_bib0020","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0021","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0022","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.clinthera.2012.02.023","article-title":"Effect of aripiprazole 2 to 15 mg\/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials","volume":"34","author":"Varni","year":"2012","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0023","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/JCP.13m08500","article-title":"A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder","volume":"75","author":"Findling","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009043.pub2","article-title":"Aripiprazole for autism spectrum disorders (ASD)","author":"Ching","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.cppeds.2018.08.015_bib0025","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1089\/cap.2012.0075","article-title":"Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change","volume":"23","author":"Mankoski","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0026","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2174\/15748847113086660073","article-title":"Second generation antipsychotics in Asperger's Disorder and high functioning autism: a systematic review of the literature and effectiveness of meta-analysis","volume":"8","author":"Sochocky","year":"2013","journal-title":"Curr Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0027","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0028","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1089\/cap.2014.0111","article-title":"A retrospective naturalistic study of ziprasidone for irritability in youth with autism spectrum disorder","volume":"25","author":"Dominick","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"10.1016\/j.cppeds.2018.08.015_bib0029","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1089\/cap.2016.0049","article-title":"Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder","volume":"26","author":"Yoon","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.cppeds.2018.08.015_bib0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00213-012-2711-3","article-title":"Paliperidone for irritability in adolescents and young adults with autistic disorder","volume":"223","author":"Stigler","year":"2012","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0031","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10803-015-2628-x","article-title":"Lurasidone for the treatment of irritability associated with autistic disorder","volume":"46","author":"Loebel","year":"2016","journal-title":"J Autism Dev Disord"},{"issue":"8","key":"10.1016\/j.cppeds.2018.08.015_bib0032","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/13543784.2017.1353600","article-title":"Lurasidone for the treatment of irritability and anger in autism spectrum disorders","volume":"26","author":"McClellan","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00787-007-0620-5","article-title":"Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial","volume":"17","author":"Miral","year":"2008","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0034","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00787-007-0656-6","article-title":"Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study","volume":"17","author":"Gencer","year":"2008","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.cppeds.2018.08.015_bib0035","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1176\/ajp.126.11.1670","article-title":"Comparison of haloperidol and fluphenazine in disturbed children","volume":"126","author":"Faretra","year":"1970","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0036","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00213-013-3263-x","article-title":"Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study","volume":"231","author":"Hsia","year":"2014","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0037","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004583-198901000-00016","article-title":"Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration","volume":"28","author":"Perry","year":"1989","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0038","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00004714-200108000-00012","article-title":"Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study","volume":"21","author":"Remington","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0039","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/JCP.0b013e318218f4a1","article-title":"Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors","volume":"31","author":"Beherec","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"10.1016\/j.cppeds.2018.08.015_bib0040","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1089\/cap.2015.0216","article-title":"Clozapine for drug-refractory irritability in individuals with developmental disability","volume":"26","author":"Wink","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0041","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S1734-1140(12)70927-1","article-title":"Drug therapy in autism: a present and future perspective","volume":"64","author":"Kumar","year":"2012","journal-title":"Pharmacol Rep"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0043","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/cap.2017.0096","article-title":"Long-acting injectable atypical antipsychotic use in adolescents: an observational study","volume":"28","author":"Fortea","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0044","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/cap.2011.0035","article-title":"Paliperidone palmitate in a child with autistic disorder","volume":"21","author":"Kowalski","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10","key":"10.1016\/j.cppeds.2018.08.015_bib0045","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40261-017-0555-7","article-title":"Effectiveness, adverse effects and drug compliance of long-acting injectable risperidone in children and adolescents","volume":"37","author":"Ceylan","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0046","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/cap.2016.0055","article-title":"Long-acting injectable antipsychotics in children and adolescents","volume":"27","author":"Lytle","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.cppeds.2018.08.015_bib0047","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0048","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1176\/appi.ps.201400222","article-title":"Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003\u20132011","volume":"66","author":"Connolly","year":"2015","journal-title":"Psychiatr Serv"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0049","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpediatrics.2010.48","article-title":"Metabolic screening in children receiving antipsychotic drug treatment","volume":"164","author":"Morrato","year":"2010","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"10.1016\/j.cppeds.2018.08.015_bib0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/cap.2013.0099","article-title":"Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole","volume":"24","author":"Wink","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0051","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaac.2016.02.016","article-title":"Weight gain and metabolic consequences of risperidone in young children with autism spectrum disorder","volume":"55","author":"Scahill","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"10.1016\/j.cppeds.2018.08.015_bib0052","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamapsychiatry.2016.1232","article-title":"Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial","volume":"73","author":"Anagnostou","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.cppeds.2018.08.015_bib0053","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jaac.2017.07.790","article-title":"A randomized, placebo-controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young people with autism spectrum disorder: open-label extension","volume":"56","author":"Handen","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.cppeds.2018.08.015_bib0054","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1007\/s10803-017-3132-2","article-title":"Brief report: metformin for antipsychotic-induced weight gain in youth with autism spectrum disorder","volume":"47","author":"Wink","year":"2017","journal-title":"J Autism Dev Disord"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1753-2000-7-31","article-title":"Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods","volume":"7","author":"Reeves","year":"2013","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0056","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.braindev.2004.06.006","article-title":"Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders","volume":"27","author":"Canitano","year":"2005","journal-title":"Brain Dev"},{"issue":"7","key":"10.1016\/j.cppeds.2018.08.015_bib0057","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","article-title":"Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder","volume":"34","author":"Rezaei","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"11","key":"10.1016\/j.cppeds.2018.08.015_bib0058","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity","volume":"62","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0059","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.biopsych.2006.09.028","article-title":"Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures","volume":"61","author":"Posey","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.cppeds.2018.08.015_bib0060","article-title":"Methylphenidate for children and adolescents with autism spectrum disorder","volume":"11","author":"Sturman","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.cppeds.2018.08.015_bib0061","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity","volume":"62","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0062","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1005548619694","article-title":"Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder","volume":"30","author":"Handen","year":"2000","journal-title":"J Autism Dev Disord"},{"issue":"2","key":"10.1016\/j.cppeds.2018.08.015_bib0063","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/YCO.0000000000000132","article-title":"An update on pharmacotherapy for autism spectrum disorder in children and adolescents","volume":"28","author":"Ji","year":"2015","journal-title":"Curr Opin Psychiatry"},{"issue":"10","key":"10.1016\/j.cppeds.2018.08.015_bib0064","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial","volume":"45","author":"Arnold","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.cppeds.2018.08.015_bib0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaac.2012.04.011","article-title":"A randomized double-blind study of atomoxetine versus placebo for attention-deficit\/hyperactivity disorder symptoms in children with autism spectrum disorder","volume":"51","author":"Harfterkamp","year":"2012","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"10.1016\/j.cppeds.2018.08.015_bib0066","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaac.2016.06.015","article-title":"Atomoxetine and parent training for children with autism and attention-deficit\/hyperactivity disorder: a 24-week extension study","volume":"55","author":"Smith","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0067","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1089\/cap.2012.0012","article-title":"Long-term treatment with atomoxetine for attention-deficit\/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study","volume":"23","author":"Harfterkamp","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0068","first-page":"77","article-title":"A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism","volume":"53","author":"Fankhauser","year":"1992","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0069","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder","volume":"12","author":"Jaselskis","year":"1992","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0070","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/cap.2006.16.589","article-title":"A prospective open trial of guanfacine in children with pervasive developmental disorders","volume":"16","author":"Scahill","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0071","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/DBP.0b013e3181739b9d","article-title":"Guanfacine in children with autism and\/or intellectual disabilities","volume":"29","author":"Handen","year":"2008","journal-title":"J Dev Behav Pediatr"},{"issue":"12","key":"10.1016\/j.cppeds.2018.08.015_bib0072","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1176\/appi.ajp.2015.15010055","article-title":"Extended-release guanfacine for hyperactivity in children with autism spectrum disorder","volume":"172","author":"Scahill","year":"2015","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.cppeds.2018.08.015_bib0073","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/s41386-018-0039-3","article-title":"A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures","volume":"43","author":"Politte","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0074","article-title":"Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents","author":"Hurwitz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.cppeds.2018.08.015_bib0075","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1007\/s10803-014-2184-9","article-title":"A systematic review of treatments for anxiety in youth with autism spectrum disorders","volume":"44","author":"Vasa","year":"2014","journal-title":"J Autism Dev Disord"},{"issue":"2","key":"10.1016\/j.cppeds.2018.08.015_bib0076","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cppeds.2017.12.001","article-title":"Antidepressant-induced activation in children and adolescents: risk, recognition and management","volume":"48","author":"Luft","year":"2018","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"8","key":"10.1016\/j.cppeds.2018.08.015_bib0077","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)","author":"Williams","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0078","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1176\/appi.ajp.2011.10050764","article-title":"A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders","volume":"169","author":"Hollander","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0079","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.npp.1300627","article-title":"A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism","volume":"30","author":"Hollander","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0081","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism","volume":"66","author":"King","year":"2009","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.cppeds.2018.08.015_bib0082","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/archpsyc.1996.01830110037005","article-title":"A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder","volume":"53","author":"McDougle","year":"1996","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0083","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1022234605695","article-title":"Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study","volume":"33","author":"Martin","year":"2003","journal-title":"J Autism Dev Disord"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0084","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/10445460152595586","article-title":"A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders","volume":"11","author":"Posey","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"10.1016\/j.cppeds.2018.08.015_bib0085","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4088\/JCP.v62n07a05","article-title":"An open trial of divalproex sodium in autism spectrum disorders","volume":"62","author":"Hollander","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0086","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/npp.2009.202","article-title":"Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders","volume":"35","author":"Hollander","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0087","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2005.15.682","article-title":"A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders","volume":"15","author":"Hellings","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0088","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s10803-012-1661-2","article-title":"Brief report: retrospective case series of oxcarbazepine for irritability\/agitation symptoms in autism spectrum disorder","volume":"43","author":"Douglas","year":"2013","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.cppeds.2018.08.015_bib0089","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1176\/ajp.2007.164.5.832","article-title":"Oxcarbazepine in youths with autistic disorder and significant disruptive behaviors","volume":"164","author":"Kapetanovic","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"9","key":"10.1016\/j.cppeds.2018.08.015_bib0090","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/cap.2015.0117","article-title":"Serum quetiapine concentration changes with concomitant oxcarbazepine therapy in a boy with autism spectrum disorder","volume":"25","author":"McGrane","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.cppeds.2018.08.015_bib0091","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Belsito","year":"2001","journal-title":"J Autism Dev Disord"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0092","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.yic.0000224787.13782.0f","article-title":"Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study","volume":"21","author":"Wasserman","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.cppeds.2018.08.015_bib0093","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.braindev.2010.08.010","article-title":"Correlation between EEG abnormalities and symptoms of autism spectrum disorder (ASD)","volume":"32","author":"Yasuhara","year":"2010","journal-title":"Brain Dev"},{"issue":"7","key":"10.1016\/j.cppeds.2018.08.015_bib0094","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/cap.2014.0019","article-title":"Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder","volume":"24","author":"Siegel","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/phar.1686","article-title":"Management of sleep disorders in children with neurodevelopmental disorders: a review","volume":"36","author":"Blackmer","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.cppeds.2018.08.015_bib0096","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.biopsych.2004.11.003","article-title":"Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder","volume":"57","author":"Tordjman","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"9","key":"10.1016\/j.cppeds.2018.08.015_bib0097","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1469-8749.2011.03980.x","article-title":"Melatonin in autism spectrum disorders: a systematic review and meta-analysis","volume":"53","author":"Rossignol","year":"2011","journal-title":"Dev Med Child Neurol"},{"issue":"18","key":"10.1016\/j.cppeds.2018.08.015_bib0098","first-page":"30042","article-title":"Low maternal melatonin level increases autism spectrum disorder risk in children","volume":"S0891-4222","author":"Braam","year":"2018","journal-title":"Res Dev Disabil"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0099","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11920-017-0782-x","article-title":"Sleep in children with autism spectrum disorder","volume":"19","author":"Souders","year":"2017","journal-title":"Curr Psychiatry Rep"},{"issue":"11","key":"10.1016\/j.cppeds.2018.08.015_bib0100","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jaac.2017.09.414","article-title":"Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder","volume":"56","author":"Gringras","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0101","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2011.02.001","article-title":"Prolonged-release melatonin for children with neurodevelopmental disorders","volume":"45","author":"De Leersnyder","year":"2011","journal-title":"Pediatr Neurol"},{"issue":"7","key":"10.1016\/j.cppeds.2018.08.015_bib0102","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.braindev.2007.12.007","article-title":"Use of clonidine in children with autism spectrum disorders","volume":"30","author":"Ming","year":"2008","journal-title":"Brain Dev"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0103","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/phar.1920","article-title":"Effectiveness of sleep-based interventions for children with autism spectrum disorder: a meta-synthesis","volume":"37","author":"Cuomo","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0104","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2869.2012.01021.x","article-title":"Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial","volume":"21","author":"Cortesi","year":"2012","journal-title":"J Sleep Res"},{"issue":"Suppl 2","key":"10.1016\/j.cppeds.2018.08.015_bib0105","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1542\/peds.2012-0900N","article-title":"Gastrointestinal conditions in children with autism spectrum disorder: developing a research agenda","volume":"130","author":"Coury","year":"2012","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0106","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1542\/peds.2013-3995","article-title":"Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis","volume":"133","author":"McElhanon","year":"2014","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eurpsy.2010.03.003","article-title":"Second-generation antipsychotics and constipation: a review of the literature","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.cppeds.2018.08.015_bib0108","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1542\/peds.2009-1878C","article-title":"Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report","volume":"125","author":"Buie","year":"2010","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0109","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10803-006-0176-0","article-title":"Physical illness, pain, and problem behavior in minimally verbal people with developmental disabilities","volume":"37","author":"Carr","year":"2007","journal-title":"J Autism Dev Disord"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11894-002-0071-6","article-title":"Autism and gastrointestinal symptoms","volume":"4","author":"Horvath","year":"2002","journal-title":"Curr Gastroenterol Rep"},{"issue":"Suppl 2","key":"10.1016\/j.cppeds.2018.08.015_bib0111","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1542\/peds.2012-0900H","article-title":"Management of constipation in children and adolescents with autism spectrum disorders","volume":"130","author":"Furuta","year":"2012","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.cppeds.2018.08.015_bib0112","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/0009922813505699","article-title":"Role of polyethylene glycol in childhood constipation","volume":"53","author":"Phatak","year":"2014","journal-title":"Clin Pediatr"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0113","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ebch.1893","article-title":"Cochrane review: osmotic and stimulant laxatives for the management of childhood constipation (review)","volume":"8","author":"Gordon","year":"2013","journal-title":"Evid Based Child Health"},{"key":"10.1016\/j.cppeds.2018.08.015_bib0114","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fncel.2017.00120","article-title":"The gut microbiota and autism spectrum disorders","volume":"11","author":"Li","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.cppeds.2018.08.015_bib0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12888-016-0887-5","article-title":"Gut to brain interaction in autism spectrum disorders: a randomized controlled trial on the role of probiotics on clinical, biochemical and neurophysiological parameters","volume":"16","author":"Santocchi","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.cppeds.2018.08.015_bib0116","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neubiorev.2015.02.009","article-title":"Fronto-striatal glutamatergic compounds in compulsive and impulsive syndromes: a review of magnetic resonance spectroscopy studies","volume":"52","author":"Naaijen","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"issue":"15","key":"10.1016\/j.cppeds.2018.08.015_bib0117","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.2174\/0929867322666150209152712","article-title":"A review on GABA\/glutamate pathway for therapeutic intervention of ASD and ADHD","volume":"22","author":"Purkayastha","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.cppeds.2018.08.015_bib0118","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s11689-016-9181-6","article-title":"Arbaclofen in fragile X syndrome: results of phase 3 trials","volume":"9","author":"Berry-Kravis","year":"2017","journal-title":"J Neurodev Disord"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0119","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10803-015-2619-y","article-title":"Pharmacological modulation of GABA function in autism spectrum disorders: a systematic review of human studies","volume":"46","author":"Brondino","year":"2016","journal-title":"J Autism Dev Disord"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0120","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10803-013-1963-z","article-title":"STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study","volume":"44","author":"Erickson","year":"2014","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.cppeds.2018.08.015_bib0121","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/DHPS.S39595","article-title":"Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder","volume":"6","author":"Frye","year":"2014","journal-title":"Drug Healthc Patient Saf"},{"issue":"7","key":"10.1016\/j.cppeds.2018.08.015_bib0122","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/npp.2016.237","article-title":"Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial","volume":"42","author":"Veenstra-VanderWeele","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0123","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0124","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.cppeds.2018.08.015_bib0125","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"4","author":"Zanos","year":"2018","journal-title":"Mol Psychiatry"},{"issue":"2","key":"10.1016\/j.cppeds.2018.08.015_bib0126","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00000542-199808000-00052","article-title":"Oral ketamine for the management of combative autistic adult","volume":"89","author":"Bachenberg","year":"1998","journal-title":"Anesthesiology"},{"issue":"8","key":"10.1016\/j.cppeds.2018.08.015_bib0127","doi-asserted-by":"crossref","first-page":"835","DOI":"10.4088\/JCP.13cr08917","article-title":"Intranasal ketamine treatment in an adult with autism spectrum disorder","volume":"75","author":"Wink","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0129","first-page":"19","article-title":"Comparing efficacy and side effects of memantine vs. risperidone in the treatment of autistic disorder","volume":"50","author":"Nikvarz","year":"2017","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0130","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/cap.2006.16.517","article-title":"A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders","volume":"16","author":"Owley","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0132","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13063-016-1266-8","article-title":"Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) \u2013 study protocol for a randomised controlled trial","volume":"17","author":"Hage","year":"2016","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0133","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1038\/tp.2017.10","article-title":"Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders","volume":"7","author":"Lemonnier","year":"2017","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0134","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00213-013-3022-z","article-title":"Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome","volume":"228","author":"Erickson","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.cppeds.2018.08.015_bib0135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpsychires.2014.07.011","article-title":"Impact of acamprosate on plasma amyloid-beta precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker","volume":"59","author":"Erickson","year":"2014","journal-title":"J Psychiatr Res"},{"issue":"6","key":"10.1016\/j.cppeds.2018.08.015_bib0136","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/cap.2011.0034","article-title":"An open-label naturalistic pilot study of acamprosate in youth with autistic disorder","volume":"21","author":"Erickson","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0137","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10803-013-1943-3","article-title":"Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder","volume":"44","author":"Erickson","year":"2014","journal-title":"J Autism Dev Disord"},{"issue":"11","key":"10.1016\/j.cppeds.2018.08.015_bib0138","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1007\/s10803-014-2144-4","article-title":"Brief report: an open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder","volume":"44","author":"Fung","year":"2014","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.cppeds.2018.08.015_bib0139","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13229-016-0088-6","article-title":"A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder","volume":"7","author":"Wink","year":"2016","journal-title":"Mol Autism"},{"issue":"2","key":"10.1016\/j.cppeds.2018.08.015_bib0140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1089\/cap.2013.0040","article-title":"Oxytocin and autism: a systematic review of randomized controlled trials","volume":"24","author":"Preti","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"10.1016\/j.cppeds.2018.08.015_bib0141","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mp.2015.162","article-title":"The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial","volume":"21","author":"Yatawara","year":"2016","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0142","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.npp.1300021","article-title":"Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders","volume":"28","author":"Hollander","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.cppeds.2018.08.015_bib0143","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0910249107","article-title":"Promoting social behavior with oxytocin in high-functioning autism spectrum disorders","volume":"107","author":"Andari","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0144","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10803-013-1899-3","article-title":"Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial","volume":"44","author":"Dadds","year":"2014","journal-title":"J Autism Dev Disord"},{"issue":"1","key":"10.1016\/j.cppeds.2018.08.015_bib0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2040-2392-3-16","article-title":"Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial","volume":"3","author":"Anagnostou","year":"2012","journal-title":"Mol Autism"},{"issue":"30","key":"10.1016\/j.cppeds.2018.08.015_bib0146","doi-asserted-by":"crossref","first-page":"8119","DOI":"10.1073\/pnas.1705521114","article-title":"Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism","volume":"114","author":"Parker","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.cppeds.2018.08.015_bib0147","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5080067","article-title":"Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data","volume":"5","author":"Bozzatello","year":"2016","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.cppeds.2018.08.015_bib0148","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122608","article-title":"The role of omega-3 fatty acids in developmental psychopathology: a systematic review on early psychosis, autism, and ADHD","volume":"18","author":"Agostoni","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.cppeds.2018.08.015_bib0149","article-title":"Omega-3 fatty acids supplementation for autism spectrum disorders (ASD)","author":"James","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cppeds.2018.08.015_bib0150","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2147\/NDT.S147305","article-title":"Supplementation of omega 3 fatty acids may improve hyperactivity, lethargy, and stereotypy in children with autism spectrum disorders: a meta-analysis of randomized controlled trials","volume":"13","author":"Cheng","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"10.1016\/j.cppeds.2018.08.015_bib0151","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1177\/0883073814531330","article-title":"Evidence of the gluten-free and casein-free diet in autism spectrum disorders: a systematic review","volume":"29","author":"Mari-Bauset","year":"2014","journal-title":"J Child Neurol"},{"issue":"2","key":"10.1016\/j.cppeds.2018.08.015_bib0152","article-title":"Gluten- and casein-free diets for autistic spectrum disorder","author":"Millward","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.cppeds.2018.08.015_bib0153","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091916","article-title":"The endocannabinoid system and autism spectrum disorders: insights from animal models","volume":"18","author":"Zamberletti","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.cppeds.2018.08.015_bib0154","doi-asserted-by":"crossref","first-page":"e905","DOI":"10.1038\/tp.2016.169","article-title":"Endocannabinoid signaling in social functioning: an RDoC perspective","volume":"6","author":"Karhson","year":"2016","journal-title":"Transl Psychiatry"},{"issue":"3","key":"10.1016\/j.cppeds.2018.08.015_bib0155","first-page":"176","article-title":"Cannabinoids in Pediatrics","volume":"22","author":"Campbell","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0156","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00004703-200610000-00029","article-title":"An open label study of the use of dronabinol (marinol) in the management of treatment-resistant self-injurious behavior in 10 retarded adolescent patients","volume":"27","author":"Kruger","year":"2006","journal-title":"J Dev Behav Pediatr"},{"issue":"5","key":"10.1016\/j.cppeds.2018.08.015_bib0157","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2174\/1871527316666170413105421","article-title":"Neurological disorders in medical use of cannabis: an update","volume":"16","author":"Solimini","year":"2017","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"4","key":"10.1016\/j.cppeds.2018.08.015_bib0158","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/cap.2008.0137","article-title":"Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit\/hyperactivity disorder symptoms in preschoolers with developmental disorders","volume":"19","author":"Ghuman","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"}],"container-title":["Current Problems in Pediatric and Adolescent Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153854421830097X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153854421830097X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T15:49:35Z","timestamp":1571932175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153854421830097X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":154,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S153854421830097X"],"URL":"https:\/\/doi.org\/10.1016\/j.cppeds.2018.08.015","relation":{},"ISSN":["1538-5442"],"issn-type":[{"value":"1538-5442","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Pediatric and Adolescent Health Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cppeds.2018.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}